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Introduction {#sec1}
============

Cell adhesion to extracellular matrix (ECM) proteins and to neighboring cells is essential for multicellular organisms. Cells perceive and respond to the composition and stiffness of the ECM through mechanotransduction via integrin class of receptors. As key regulators of cell fate, e.g., survival, proliferation, and migration, integrins are essential for embryonic development, and their aberrant signaling fuels numerous diseases, including inflammation, tumor growth, chemoresistance, and metastasis.

Several adaptor proteins transduce integrin signals by directly binding to the cytoplasmic tails of β-integrins ([@bib32]). Among them, only talin and kindlin are known to be indispensable for integrin activation ([@bib58], [@bib8]). The phosphotyrosine-binding (PTB)-like module in talin\'s FERM3 domain binds to the membrane-proximal NPxY motif of β-integrin cytoplasmic tails. Kindlin is also a FERM3 domain-containing protein that binds to the membrane distal NPxY motif on integrin tails. Structural, biochemical, and mutational approaches revealed that talin-mediated integrin activation results in conformational changes in the receptor\'s transmembrane helix ([@bib29], [@bib30]) and how such activation requires first the reversal of an intramolecular autoinhibitory contact within talin, between its FERM3-PTB and its rod domains ([@bib60], [@bib63], [@bib21], [@bib18]). By contrast, kindlin does not have the ability to directly alter the conformation of the integrin transmembrane helix and instead augments integrin activation in cooperativity with talin ([@bib4]), without which the conformational shift of integrins from the low- to high-affinity state cannot occur and maximal activation is not possible ([@bib9], [@bib8]).

Regarding mechanistic insights into how adaptor binding translates to integrin activation, gathering evidence suggests that activation occurs by fine-tuning the affinity of talin and kindlin for integrins. Talin\'s affinity for integrins, for example, can be regulated either through proteolytic relief of auto-inhibition or through membrane recruitment and molecular allostery upon direct binding of phosphoinositides to the FERM3 domain ([@bib47], [@bib67], [@bib28], [@bib31], [@bib22]). In the case of kindlin, however, despite the discovery of numerous interacting partners ([@bib58], [@bib17], [@bib7]) that coordinate the activation of focal adhesion kinase (FAK), Rac1, and the Arp2/3 complex within the so-called adhesome complex ([@bib58], [@bib7], [@bib69], [@bib64]), who or what may fine-tune the affinity of kindlin for integrins remains unknown and whether such fine-tuning enhances initial integrin activation, clustering, and adhesion strengthening remains elusive.

Besides talin and kindlin, we ([@bib38]) and others ([@bib34], [@bib33]) have recently reported that exposing cells to ECM also triggers the tyrosine phosphorylation of another adaptor protein, GIV, and that focal adhesions (FAs) serve as the major hubs for tyr-based mechanochemical signaling via GIV. GIV is a guanine nucleotide exchange factor (GEF) for trimeric GTPase, Gi ([@bib19], [@bib26]), and is an actin remodeler ([@bib16]). Published work has shown that GIV (and Gαi via GIV) interacts exclusively with ligand-activated β1-integrins and GIV\'s GEF function is essential for the subsequent activation of Gαi in response to stimuli ([@bib34], [@bib38]). GIV-dependent Gi activation and release of "free" Gβγ-heterodimer modulates multiple downstream signals including FAK activation, remodeling of the actin cytoskeleton, and Rac1 and PI3K-dependent signaling, resulting in enhanced haptotaxis and invasion ([@bib34]). These signals and cellular phenotypes are further reinforced via a forward-feedback loop in which activated FAK phosphorylates GIV and that such phosphorylation further enhances PI3K-Akt signaling, the integrity of FAs, and cell adhesion and motility ([@bib33], [@bib38]). Spatially restricted signaling via tyrosine phosphorylated GIV at the FAs is enhanced during cancer metastasis ([@bib43]). Despite these insights, how GIV binds integrins remained unclear; because they co-immunoprecipitated from cells, but recombinant GIV and β-integrin cytoplasmic tails did not interact *in vitro*, the interaction was assumed to be indirect ([@bib38]).

We set out to investigate how GIV gains access to β-integrin cytoplasmic tails but unexpectedly stumbled upon an intermolecular interplay between GIV, kindlin, and β1-integrin. Findings help answer some of the fundamental unanswered questions, e.g., how GIV may bind integrins to impact downstream signaling and how kindlin may bring about maximal integrin activation; they also provide mechanistic insights into how cooperativity between the two adaptors may be essential for both.

Results and Discussion {#sec2}
======================

GIV Interacts with Ligand-Activated β1-Integrins Indirectly via Kindlin-2 {#sec2.1}
-------------------------------------------------------------------------

Prior work had shown that GIV indirectly associates with β1-integrins early (within minutes) during cell adhesion and localizes to nascent focal adhesions (FAs) at the cell periphery well before integrins cluster and FAs mature. Because integrin activation and clustering, two of the earliest steps of cell adhesion, require sequential recruitment of the adaptor proteins talin, then kindlin, and finally, tensin ([@bib1], [@bib8], [@bib46]), we hypothesized that GIV may interact with one or more of these adaptors. To test this hypothesis, we carried out pull-down studies using recombinant GST-tagged integrin-binding FERM3/PTB modules of the key adaptor proteins (Talin, Kindlin, and Tensin) and His-tagged C-terminal fragment of GIV (GIV-CT; ∼ 210 aa). To avoid common problems encountered when generating protein fragments (misfolding, degradation, unforeseen/undesired mutations, all leading to non-functional proteins, we refrained from creating new constructs and instead curated previously published constructs that were validated in various biochemical or crystallography studies to interrogate integrin biology and sequenced them to confirm accuracy (see [Methods](#sec3){ref-type="sec"}). As for GIV-CT, it has previously been shown to bind cytoplasmic tails of multiple growth factor receptors ([@bib36]), G proteins ([@bib19]), FAK ([@bib38]), and p85α-PI3K ([@bib37]); prior work also showed that GIV-CT is sufficient to trigger cancer cell invasion ([@bib39], [@bib44]). Among the three Kindlins (K1--3), we chose to study kindlin-2 (K2) because, unlike K1 and K3, which are expressed in restricted cells/tissues (i.e., epithelial and hematopoietic system, which express GIV at very low levels \[[@bib16]\]), K2 is expressed ubiquitously ([@bib49]). We found that GIV specifically bound the FERM3-PTB module of K2 and to the PTB module of tensin but not to the FERM2-PTB module of talin ([Figure 1](#fig1){ref-type="fig"}A). Because GIV was previously shown to accumulate early during cell adhesion within nascent FAs at the cell periphery ([@bib38]), where K2 is known to exist at a 1:1 ratio with β1-integrins ([@bib56]), and tensin on the other hand is typically enriched later in FAs during the course of tension-dependent maturation ([@bib68]), we chose to further dissect the nature and relevance of the GIV•K2 interaction. Full-length GIV (from cell lysates) could also bind GST-K2, but little or no binding was observed with GST-β-integrin tails ([Figure 1](#fig1){ref-type="fig"}B). We also confirmed that the reverse was also true, in that, when GST-GIV-CT was immobilized on glutathione beads, it could directly bind His-K2 ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}A); to our surprise, in this assay, K2 bound GIV-CT much better than it bound our positive control (GST-β1-CT). Because one prior study ([@bib34]) claimed the existence of a possible weak, but direct, interaction between GIV\'s N terminus (GIV-NT; aa 1--256) and the cytoplasmic tail of β1-integrin, we compared side by side the ability of the N- and C-terminal fragments to bind GST-β1-CT and K2. We found that neither the C nor the N terminus of GIV bound the cytoplasmic tail of integrin β1 to any appreciable degree when compared with the binding of GIV-CT to K2 ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Furthermore, co-immunoprecipitation studies confirmed that the interaction we observe between tagged recombinant proteins *in vitro* occurs also between full-length endogenous GIV and kindlin2 proteins in cells ([Figure 1](#fig1){ref-type="fig"}D). These findings demonstrate that the C terminus of GIV directly and specifically binds the integrin-adaptor K2 and suggest that previously reported interactions of GIV and G protein, Gi with ligand-activated β1-integrin in cells are likely to be indirect (via K2). Indeed, we confirmed this to be true, because neither GIV nor Gαi was detectable within β1-integrin-bound complexes when we depleted HeLa cells of endogenous K2 but they were readily detectable when a small interfering RNA (siRNA)-resistant GFP-tagged K2 was exogenously expressed in these cells ([Figure 1](#fig1){ref-type="fig"}E). Although it is possible that impaired formation of focal adhesions in cells without kindlin-2 may preclude the GIV•β1-integrin interaction, together with the biochemical evidence of direct interaction and interactions observed in cells, our findings indicate that GIV interacts with ligand-activated β1-integrins indirectly via kindlin-2.Figure 1GIV Binds Kindlin-2 and Is Required for kindlin Recruitment to Integrin β1 at Focal Adhesions and for Maximal Integrin Activation(A) GST pull-down assays were performed using equal aliquots of recombinant His-GIV-CT (aa 1,660--1,870; ∼3 μg) and various FERM3/PTB fragments of GST-tagged adaptor proteins known to bind integrin-β receptors. Bound His-GIV-CT and various GST ligands were visualized by immunoblotting using an anti-His mAb and an anti-GST pAb, respectively.(B) Equal aliquots of lysates of MDA-MB-231 cells were used as source for full-length endogenous GIV in GST pull-down assays with GST-Kindlin 2 (K2), GST-β1, or GST-β3 proteins. Bound GIV was visualized by immunoblotting using anti-GIV-CT rabbit polyAb. Equal loading of GST proteins was confirmed by Ponceau S staining.(C) GST pull-down assays were performed using recombinant His-Kindlin 2 (6xHis-SUMO-Kindlin2Δ \[[@bib35]\]) and GST-GIV-CT (aa 1,623--1,870). Bound kindlin-2 was analyzed by immunoblotting with anti-His mAb. GST proteins were visualized by Ponceau S staining. GST-β1 and GST-β3 integrin tails were used as positive and negative controls, respectively. See also [Figure S1](#mmc1){ref-type="supplementary-material"}A for bar graphs displaying quantification.(D) Immunoprecipitation studies with anti-Kindlin2 (K2) antibody on lysates of control (siC) or kindlin-2-depleted (by siKindlin-2) HeLa cells. Immune complexes were analyzed for GIV, Integrin- β1, and Kindlin2 by immunoblotting (IB).(E) Control (siC) or kindlin-2-depleted (by siKindlin-2) HeLa cells reconstituted or not with GFP-Kindlin-2, grown on poly-D-Lysine-coated surface, were stimulated (+) or not (−) by plating on collagen-coated surface for 30 min before lysis. Equal aliquots of lysates (Input cell lysates) were subjected to immunoprecipitation using anti-β1-integrin antibody. Immune complexes were analyzed for total (t)GIV, β1-integrin, and Gαi3 by immunoblotting. The differences in levels of tGIV in input lysates likely reflects differential extraction by Triton X-100 in cells plated on poly-D-Lysine versus collagen-plated coverslips.(F) MDA-MB-231 cells depleted (shGIV) or not (shC) of GIV by shRNA were analyzed for GIV and tubulin by immunoblotting with respective antibodies.(G) Cell lines in (F) were grown on poly-D-Lysine-coated surface and were stimulated by plating on collagen-coated cover slips for 30 min, fixed, and stained for active β1-integrin (green; using a conformational specific antibody, clone 9EG7), phalloidin (blue; actin), and total β1-integrin (red) and analyzed by confocal microscopy. Representative deconvolved images are shown. Insets were analyzed by rendering 3D surface plots, and line scans were taken to generate RGB plots using ImageJ.(H and I) FACS histograms (H, I) of cells in (F) showing cell-surface expression of total (H) and active β1 (I), as measured by 9EG7 staining. C, IgG negative control.(J) Bar graphs showing fold change in the proportion of activation of β1-integrin (active/total) in (H) and (I). Data are represented as mean ± SEM (n = 3); ∗∗p=\<0.01.(K) Cells in (G) were fixed and stained for active β1-integrin (green; using a conformational specific antibody, clone 9EG7), phalloidin (blue; actin), and K2 (red) and analyzed by confocal microscopy. Representative deconvolved images are shown. Insets were analyzed by rendering 3D surface plots, and line scans were taken to generate RGB plots using ImageJ.

GIV Is Required for Integrin Activation, Formation of β1-integrin•Kindlin Complexes at Focal Adhesions {#sec2.2}
------------------------------------------------------------------------------------------------------

Because K2 is believed to be indispensable for integrin activation ([@bib58], [@bib8]), next we analyzed if GIV, which is co-recruited with K2 is also required for the same. To this end, we used control and GIV-depleted MDA-MB-231 breast cancer cells, a model system that was previously used by others to implicate GIV\'s role in integrin-dependent downstream activation of the PI3K-Akt and RhoA pathways ([@bib34]), stimulated them by plating on collagen-coated cover slips and stained them with a previously validated conformation-sensitive rat anti-CD29 9EG7 antibody. We found that cells without GIV had significantly reduced integrin activation, both within nascent FAs in the cell periphery and within mature FAs ([Figure 1](#fig1){ref-type="fig"}G), indicating that much like K2, GIV is also required for β1-integrin activation. Flow cytometry studies using the same antibody further confirmed that activation of β1-integrins on the cell surface was diminished in MDA-MB-231 cells without GIV ([Figures 1](#fig1){ref-type="fig"}H--1J). When we monitored by immunofluorescence the recruitment of endogenous K2 in these cells, we unexpectedly found that the colocalization of active β1 and K2 was also reduced in GIV-depleted cells ([Figure 1](#fig1){ref-type="fig"}H), indicating that GIV may somehow enable the formation of active β1-integrin•K2 complexes at the FAs. Although the levels of total β1-integrin were reduced at the cell periphery in GIV-depleted cells, immunoblots revealed that the levels of the protein were not reduced ([Figure 1](#fig1){ref-type="fig"}F) but instead redistributed to vesicular structures at the center of the cell, which could represent some endocytic compartment. Although GIV-depleted cells did not always spread as well (quantified later in-depth), the findings in [Figures 1](#fig1){ref-type="fig"}G--1H were observed in GIV-depleted cells that had spread to an equivalent degree as control cells, indicating that GIV may impact integrin activation and K2 recruitment to integrins regardless of cell spreading. Taken together, we conclude that GIV is recruited to the cytoplasmic tails of β1-integrin indirectly via its ability to bind the K2 adaptor and that GIV may be a necessary component of integrin activation and for the formation of active-β1•K2 complexes. Furthermore, depletion of GIV was associated with reduced activation of β1-integrin in two additional cell lines, HeLa and Cos7, both previously used to study GIV\'s role in downstream integrin signaling ([@bib38], [@bib43]) ([Figure S1](#mmc1){ref-type="supplementary-material"}C). These findings suggest that our findings in MDA-MB-231 cells may be relevant in other cell lines.

The C Terminus of GIV Binds Kindlin\'s FERM3-PTB Domain via a Non-canonical Short Linear Motif {#sec2.3}
----------------------------------------------------------------------------------------------

β1-Integrins bind the FERM3-PTB modules of talin and kindlin via canonical mechanisms that involve two conserved NPxY motifs on the cytoplasmic tail of the receptor. Because GIV lacks a similar motif, we hypothesized that the mechanism of GIV•K2 interaction may be non-canonical. The first clues into the mechanism came from a previously solved NMR structure of tensin-PTB bound to a peptide derived from the protein Deleted in Liver Cancer (DLC1) revealing a non-canonical mode of binding to PTB/FERM3-PTB modules ([@bib11]). A sequence alignment showed that the core sequence "Pro(P)-Gly(G)-x-Phe(F)" in DLC1 that was previously implicated in binding tensin-PTB was evolutionarily conserved within the C terminus of GIV ([Figures 2](#fig2){ref-type="fig"}A--2C); the Phe(F) within this motif was determined to contribute significantly to the strength of the interaction by filling a shallow pocket within the PTB domain of tensin ([Figure 2](#fig2){ref-type="fig"}A). This putative PTB-binding short linear interaction motif (SLIM) in GIV-CT is situated downstream of the GEM motif that GIV uses to bind and activate Gαi and is within a stretch of sequence that was predicted to have the highest degree of disorder ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C). This region has previously been shown to also fold into an SH2-like module upon recognizing phosphotyrosines on the cytoplasmic tails of diverse ligand-activated growth factor RTKs ([@bib36]) ([Figure S2](#mmc1){ref-type="supplementary-material"}D). This motif also appeared to be evolutionarily young, i.e., conserved only in higher mammals ([Figure 1](#fig1){ref-type="fig"}C), much like GIV\'s SH2-like module ([@bib36]).Figure 2Identification and Validation of a Short Linear Motif (SLIM) in GIV that Directly Binds the FERM3(F3)-PTB Module in Kindlin-2 (K2)(A) Sequence alignment between the C terminus of GIV and DLC1 (which binds Tensin via non-canonical mechanisms) using ClustalW and Boxshade revealed a conserved putative SLIM \[PGxF\] (left), which was implicated in binding the PTB module of Tensin (NMR of DLC1-bound Tensin co-complex, right).(B) Bar diagram showing the various modules in GIV. The PGxF SLIM is located within the C-terminal stretch of GIV, which is largely disordered (see [Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C).(C) Sequence alignment of the C terminus of GIV shows that the PGxF SLIM is evolutionarily young (only conserved in higher organisms). The relative positions of this and other SLIMs (that bind G proteins, PI3-kinase) and modules (that facilitate RTK binding) within the intrinsically disordered C terminus are shown in [Figure S2](#mmc1){ref-type="supplementary-material"}D.(D) GST pull-down assays were performed using lysates of Cos7 cells as source of full-length GIV with GST-Tensin-3 SH2 and SH2+PTB fragments. Bound proteins were analyzed by immunoblotting with anti-His mAb.(E) GST pull-down assays were performed using WT or ^1741^PGxA^1744^ (F1744A) mutant His-GIV-CT and GST-Tensin-3 (SH2+PTB).(F) GST pull-down assays were performed using WT or ^1741^PGxA^1744^ (F1744A) mutant His-GIV-CT and GST-Kindlin-2 (F3-PTB).(G) Bar graphs display the relative binding of His-GIV-CT to GST proteins in (F). Data are represented as mean ± SEM (n = 5); ∗∗p=\<0.01.(H) GST pull-down assays were performed using of His-GIV-CT WT or various mutants targeting its PGxF sequence and GST-Kindlin-2 (F3-PTB).(I--K) GST pull-down assays were performed using GST-K2 (aa 571--680, \[I\]) and aa 564--680, \[J\]) WT or a QW/AA mutant proteins immobilized on glutathione beads and His-GIV-CT (aa 1,660--1,870). Bound proteins were analyzed as in (D). Bar graphs (K) display the relative binding of His-GIV-CT to GST-K2 proteins in (H) and (I). Data are represented as mean ± SEM (n = 5); ∗∗p=\<0.01.(L) A structural model built using the solved structures of DLC1-bound Tensin and Integrin-bound K2 as templates predicted that the FERM3-PTB module of K2 (gray ribbon) may simultaneously bind the non-canonical PGxF sequence within the C terminus of GIV (red) as well as the canonical NPxY sequence on the cytoplasmic tail of β1-integrins (black) via two distinct binding surfaces. These surfaces are exposed also when K2 is dimerized (see also [Figure S4](#mmc1){ref-type="supplementary-material"}).

We asked if the putative PTB-binding SLIM in GIV-CT is functional. First, using GST-tagged SH2 and PTB fragments of tensin, we confirmed that full-length GIV specifically binds the PTB domain of tensin ([Figure 2](#fig2){ref-type="fig"}D). We found that the wild-type (WT), but not a mutant, His-GIV-CT protein in which the Phe(F) within the PGxF sequence is mutated to alanine (PGxA) could bind GST-Tensin-PTB ([Figure 2](#fig2){ref-type="fig"}E), which confirmed that the tensin-PTB•GIV-CT interaction is direct that it requires the intact PGxF SLIM. When we carried out similar assays, but replaced GST-tensin-PTB with GST-K2-FERM3-PTB, we observed identical results ([Figures 2](#fig2){ref-type="fig"}F and 2G), which confirmed that the K2-FERM3-PTB•GIV-CT interaction is also direct and that it too requires the intact PGxF SLIM. Using pull-down assays with GST-K2 and an array of His-tagged GIV-CT mutants that perturb the core PGxF SLIM, we further determined the relative contributions of the various residues within the SLIM: mutating the Pro(P) and Gly(G) to Ala(A) had a partial effect on the interaction, whereas mutating the Phe(F) was the most disruptive ([Figure 2](#fig2){ref-type="fig"}H). As expected, based on the location of the PGxF motif within the C terminus of GIV ([Figure S2](#mmc1){ref-type="supplementary-material"}D), none of the mutants impacted GIV\'s ability to bind Gαi ([Figure S3](#mmc1){ref-type="supplementary-material"}). These studies provided the rationale for the use of the PGxA single point mutant in all further studies as a precise tool to specifically dissect the functional relevance of the GIV•K2 interaction.

We then asked if perturbing the PTB-like conformation within the FERM3 module of K2 impacts the GIV•K2 interaction. To this end, we used a previously validated mutant in which Glu(Q)^614^Try(W)^615^ is mutated to AA in the FERM3 subdomain of K2, which impairs PTB-like folding and recognition of canonical NPxY sequences on β-integrins ([@bib41], [@bib52]). Defective integrin activation in cells expressing this K2 mutant has previously been attributed to its inability to assemble the K2•β-integrin interface ([@bib3], [@bib65]) ([@bib41], [@bib52], [@bib46]). Using two different GST-K2 constructs varying slightly in their construct boundaries (one K2 construct \[aa 571--680; [Figure 2](#fig2){ref-type="fig"}I\] was used by others to characterize the K2•β1 interaction *in vitro* and in cells \[[@bib46]\] and another construct was generated by us \[aa 568--680; [Figure 2](#fig2){ref-type="fig"}J\] and spans the complete FERM3 module), we found that this PTB-defective QW\>AA mutant K2 is required for not just binding the NPxY sequence on β-integrins but also for binding GIV ([Figures 2](#fig2){ref-type="fig"}I--2K), indicating that the QW\>AA K2 mutant is non-selective, in that the mutations impair both interactions indiscriminately. Because multiple groups observed impaired integrin activation in cells expressing the QW\>AA K2 mutant, and we observe similar defects in activation in GIV-depleted cells ([Figures 1](#fig1){ref-type="fig"}G and 1H), it is possible that the observed defect in the QW\>AA K2-expressing cells is not just due to impaired K2•β-integrin interaction but equally likely to be due to impaired K2•GIV interaction. Hence, to specifically study the impact of the GIV•K2 interaction, we used the newly identified PGxA point mutant of GIV that is deficient in binding to K2 in all subsequent assays.

The GIV•Kindlin-2 Interaction Allosterically Enhances Kindlin\'s Affinity for β1-Integrin {#sec2.4}
-----------------------------------------------------------------------------------------

Next, we asked if and how binding of GIV to K2 impacts the K2•β1-integrin interaction. Three possible scenarios were considered: (1) GIV and β1-integrin may compete for the same site or bind on overlapping sites on K2, and if so, their interactions will be mutually exclusive; (2) they may each bind K2 non-competitively via two interfaces without steric hindrances, and if so, they may bind concurrently and exist as ternary GIV•K2•β1-integrin complexes; (3) they may bind non-competitively at distinct sites on K2 but allosterically impact (either inhibit or augment) each other\'s' ability to bind K2. Superimposition of the DLC1(PGxF)•tensin complex structure ([@bib11]), the recently solved β1•K2 co-complex structure ([@bib35]) and a homology model of K2 (built using tensin-PTB as a template \[[Figure 2](#fig2){ref-type="fig"}L\]), suggested that the canonical and non-canonical modes of binding of K2 to β1-integrin and GIV, respectively, may use two distinct interfaces and remain compatible with the assembly of ternary GIV•K2•β1-integrin complexes in both monomeric and dimeric states of K2 ([Figure S4](#mmc1){ref-type="supplementary-material"}). We carried out a series of biochemical assays using recombinant proteins designed to look for intermolecular competition for interacting surfaces and/or the formation of co-complexes *in vitro*. In these assays, two components were kept constant, whereas the amount of the third component was varied. Increasing His-β1-CT (which contains the NPxY motif recognized by K2) did not displace His-GIV-CT from GST-K2; instead, we unexpectedly observed an enhanced coupling of GIV within a narrow range of concentration of β1-CT, exclusively when His-β1-CT and His-GIV-CT are both present in equimolar concentrations ([Figure 3](#fig3){ref-type="fig"}A). Similarly, increasing His-GIV-CT enhanced the coupling of His-K2 to GST-β1-CT only within a narrow range of concentration of His-GIV-CT, exclusively when His-K2 and His-GIV-CT are both present in equimolar concentrations ([Figure 3](#fig3){ref-type="fig"}B). Finally, when added in equimolar amounts, His-K2 enhanced the coupling of WT but not the PGxA mutant His-GIV-CT to GST-β1-CT ([Figure 3](#fig3){ref-type="fig"}C). Because these findings were observed consistently, with different protein preparations, the results appear to be most consistent with scenario \#3; i.e., GIV and β1-CT may bind K2 non-competitively to assemble ternary complexes when present at optimal stoichiometry ([Figures 3](#fig3){ref-type="fig"}A--3C). Under the conditions tested, we found that binding of either protein to K2 allosterically augmented the binding of the other only when GIV, β1-CT, and K2 are all present in equimolar amounts ([Figures 3](#fig3){ref-type="fig"}A and 3B).Figure 3The K2•GIV Interaction Allosterically Augments the K2•β1-integrin Interaction and *Vice Versa*, when Present in Equimolar Proportions, Enhances K2 Recruitment to Focal Adhesions and β1-Integrin Activation(A) GST pull-down assays were performed using fixed concentrations of GST-Kindlin-2-F3-PTB (GST-K2; 0.25 μg) and His-GIV-CT (aa 1,660--1,870; 1 μg) and increasing concentrations of His-β1-integrin tail, as indicated. Bound GIV was assessed by immunoblotting with anti-His mAb. Equal loading of His-GIV-CT was confirmed by SDS PAGE, and the increasing amounts of His-β1 was monitored by dot blot (input; lower panel).(B) GST pull-down assays were performed using equal aliquots of GST-β1-integrin tail (2.5 μg) and full-length His-Kindlin 2 (K2) at equimolar concentrations and increasing amounts of His-GIV-CT (aa 1,660--1,870). GST-β1-bound proteins were assessed by immunoblotting using anti-His mAb and anti-GIV polyclonal Ab.(C) GST pull-down assays were performed using GST-β1 in combination with His-GIV-CT-WT or PGxA (aa 1,660--1,870) and full-length His-Kindlin 2 (K2). GST-β1-bound proteins were assessed using anti-His mAb and anti-GIV polyclonal Ab.(D and E) GIV-depleted MDA-MB-231 cells stably expressing Flag-GIV-WT or PGxA constructs were grown on poly-D-Lysine coated surface, resuspended and plated on collagen-coated coverslips for 30 min, fixed, and stained for active β1-integrin (green; using a conformational specific antibody, clone 9EG), phalloidin (blue; actin), and either total β1-integrin (D; red) or kindlin-2 (E; red) and analyzed by confocal microscopy. Representative deconvolved images are shown. Insets were analyzed by rendering 3D surface plots, and line scans were taken to generate RGB plots using ImageJ.(F and G) FACS histograms of cells in (D) showing cell-surface expression of total (F) and active β1 (G), as measured by 9EG7 staining. C, IgG negative control.(H) Bar graphs showing fold change in the proportion of activation of β1-integrin (active/total) in (F) and (G). Data are represented as mean ± SEM (n = 4); ∗∗p = \< 0.01.

Next, we asked if the allosteric impact of the K2•GIV interaction we observe *in vitro* translates to augmentation of K2•β1-integrin interaction at FAs and β1 activation in cells. To this end, we monitored by immunofluorescence activation of β1-integrins in response to collagen and the recruitment of endogenous K2 to these active receptors in GIV-depleted MDA MB-231 cells stably expressing GIV-WT or PGxA. We found that, compared with cells expressing GIV-WT, those expressing GIV-PGxA had reduced integrin clustering and activation, as determined using conformational anti-CD29 9EG7 antibodies ([Figure 3](#fig3){ref-type="fig"}D). As expected, with fewer active β1-integrins, the extent of β1•K2 co-localization was also reduced ([Figure 3](#fig3){ref-type="fig"}E). FACS analyses further confirmed that the extent of activation of β1-integrin was indeed suppressed in the GIV-PGxA mutant ([Figures 3](#fig3){ref-type="fig"}F--3H). Together, these findings indicate that the K2•GIV interaction augments the formation of GIV•K2•β1 complexes and is required for maximal activation of β1-integrins in cells. Such augmentation may be highly regulated by protein stoichiometry and only occur within narrow ranges of protein concentrations. These findings are in keeping with prior observations that much like K2 depletion, K2 overexpression can also cause suppression of β1-integrin activation ([@bib23]).

The GIV•Kindlin-2 Interaction Enhances Tumor Cell Adhesion, Invasion, Integrin Signaling {#sec2.5}
----------------------------------------------------------------------------------------

Next, we asked how the newly defined GIV•kindlin-2 interaction impacts cellular phenotypes. Prior studies have shown that GIV is required for signal amplification downstream of ligand-activated β1-integrins via its ability to directly bind and activate Gαi and Class 1 PI3-kinase; the readouts used were cell adhesion and spreading; haptotaxis; activation of the PI3K→Akt, FAK→pY1764GIV, and RhoA→myosin light chain (MLC2) signaling axes; the degree of maturation of FAs with sequential recruitment of paxillin and vinculin proteins; and activation of FAK ([@bib34], [@bib33], [@bib38]). If these downstream events were dependent on GIV\'s ability to bind ligand-activated β1-integrins, we hypothesized that uncoupling GIV from β1-integrins will impair them all. Alternatively, if GIV\'s ability to trigger G protein and PI3K signaling is independent of its ability to bind and activate β1-integrins, we expected that uncoupling GIV from β1-integrins will have little or no impact on these readouts. To determine which scenario may be true, we analyzed these readouts in GIV-depleted MDA MB-231 cells (by a shRNA targeting its 3′ UTR \[[Figure 4](#fig4){ref-type="fig"}A\]; [@bib38]) stably expressing GIV-WT and GIV-PGxA that were acutely stimulated by plating on collagen. We found that, much like shGIV cells, those expressing the GIV-PGxA mutant was impaired in cell adhesion ([Figures 4](#fig4){ref-type="fig"}A--4C), cell spreading ([Figure 4](#fig4){ref-type="fig"}D), and haptotaxis along a serum gradient through Matrigel inserts ([Figures 4](#fig4){ref-type="fig"}F--4I). These phenotypic changes were accompanied also by significant impairment of GIV ([Figures 4](#fig4){ref-type="fig"}J, 4K, [S5](#mmc1){ref-type="supplementary-material"}A, and S5B) and Akt phosphorylation ([Figures 4](#fig4){ref-type="fig"}J and [S5](#mmc1){ref-type="supplementary-material"}B), activation of FAK ([Figures 4](#fig4){ref-type="fig"}L and [S5](#mmc1){ref-type="supplementary-material"}C), and phosphorylation of MLC2 ([Figures 4](#fig4){ref-type="fig"}M and [S5](#mmc1){ref-type="supplementary-material"}D). We used phospho-MLC2 as a surrogate marker of RhoA activity because multiple prior studies ([@bib48], [@bib15], [@bib2]) have shown that RhoA activity drops down to levels below detection during cell adhesion, and hence, monitoring pMLC2 is a more reliable readout of GIV-dependent RhoA activity during integrin signaling ([@bib34]). Because all these impairments we observed in cells expressing the K2-binding-deficient PGxA mutant of GIV were previously observed in cells without GIV, or those expressing single point mutants of GIV that selectively impair its ability to bind and activate Gαi and PI3K (see [Figure 4](#fig4){ref-type="fig"}M), we conclude that the GIV•K2 interaction may be an essential upstream event for integrin-coupled downstream activation of Gαi and PI3K. When the interaction is severed (as occurs in cells expressing the PGxA mutant GIV), none of the signaling pathways are effectively triggered, indicating that binding of GIV to integrins within the GIV•K2•β1 complexes is a pre-requisite step.Figure 4The K2•GIV Interaction Is Required for Tumor Cell Adhesion, Spreading, and Invasion through the ECM(A) Whole-cell lysates of control (shC) or GIV-depleted (shGIV) MDA-MB 231 cells stably expressing GIV-WT or the K2-binding deficient PGxA mutant was analyzed for GIV and tubulin by immunoblotting.(B) MDA-MB 231 cell lines in (A) were grown on poly-D-Lysine-coated surface, resuspended, and plated on 12-well collagen-coated plates for 30 min before being fixed in 4% PFA and stained with crystal violet. Cells were visualized and imaged by light microscopy. Representative images are shown.(C) Bar graphs display the relative numbers of adherent cells per field, as determined using ImageJ. Data are represented as mean ± SEM (n = 4); ∗p = \< 0.05(D and E) Adherent MDA-MB 231 cells in (B) were further analyzed for attachment-induced cell spreading at higher magnification. Representative images are shown (D) and quantification of percent spreading is displayed as bar graph I. Data are represented as mean ± SEM (n = 4); ∗∗∗∗p=\<0.0001.(F) Schematic diagram showing the serum gradient-induced haptotaxis assay conditions used in (G)--(I).(G--I) MDA-MB 231 cell lines in (A) were analyzed for the ability to invade through Atrigel-coated transwells. The number of cells that successfully invaded within 24 h was imaged (G and H) and quantified using ImageJ and displayed as bar graphs (I). Data are represented as mean ± SEM (n = 4); ∗∗p=\<0.01, ∗∗∗∗p=\<0.0001.(J--L) MDA-MB 231 cells were grown on poly-D-Lysine and stimulated acutely by plating on collagen-coated plates as in (B) and lysed on plate after indicated periods of time, and equal aliquots of lysates were then analyzed for phospho(p) and total (t) proteins as indicated. See also [Figure S5](#mmc1){ref-type="supplementary-material"} for quantification of biologically independent experiments.(M) Schematic summarizing the post-receptor pathways previously shown to be impacted by GIV, and the specific approaches (GIV depletion or mutants) that were used to conclude the same. Orange arrows: Positive feedforward loop of signaling. The mutation F1685A specifically impairs GIV\'s ability to bind and activate Gαi ([@bib19]). The mutation Y1764/98F specifically impairs GIV\'s ability to bind and activate PI3K ([@bib37]) and enhance the PI3K↔FAK feedforward loop ([@bib38]).

Consistent with the observed impairment in integrin signaling, we also found by immunofluorescence/confocal microscopy that the abundance of paxillin and vinculin-positive structures and the activation of FAK in the PGxA-cells were reduced ([Figure 5](#fig5){ref-type="fig"}A). To determine if the GIV•K2 interaction persists later in mature FAs, we used two-color super-resolution stimulated emission depletion (STED) microscopy ([@bib24], [@bib27]) enabling a lateral resolution of ∼40 nm to assess nanoscale co-localization of endogenous pYGIV and K2 within focal adhesions. Prior studies using STED ([@bib55], [@bib12]) have revealed the superiority of this approach over conventional microscopy for assessing the organization of FAs into nanometer-sized clusters of multi-protein assemblies. We observed nanoscale co-localization between pYGIV and K2 within mature FA-structures that were positive for paxillin ([Figure 5](#fig5){ref-type="fig"}B); compared with GIV-WT cells, such structures were far fewer and virtually lacking in cells expressing the PGxA mutant. Quantification of these paxillin-positive structures confirmed a significant reduction in the number and size of mature FA-like structures in the PGxA cells ([Figures 5](#fig5){ref-type="fig"}C and 5D).Figure 5The K2•GIV Interaction Is Necessary for the Maturation of Focal Adhesions (FA) and for Triggering the FA-Localized FAK→pYGIV Signals(A) GIV-depleted MDA-MB-231 cells stably expressing GIV-WT or GIV-PGxA constructs were grown on poly-D-Lysine-coated surface, resuspended, and plated on collagen-coated coverslips for 30 min, fixed, and stained for phalloidin (actin; blue), bona fide FA structural or signaling components (i.e., Vinculin \[top\], pYFAK \[Y397; middle\], or Paxillin \[lower\]; green), and pYGIV (red) and analyzed by confocal microscopy. Representative deconvolved images are shown. Insets were analyzed by rendering 3D surface plots, and line scans were taken to generate RGB plots, both using ImageJ.(B) STED super-resolution microscopy was carried out on cells in (A) to analyze K2 colocalization with pYGIV (top) or paxillin (bottom). Representative deconvolved images are shown. Insets were analyzed by rendering 3D surface plots and RGB plots as in (A).(C and D) The Paxillin-stained images in (A) were used to quantify focal adhesion plaque number (C) and size (area; D) with ImageJ.

Taken together, these findings implicate the GIV•K2 interaction in some of the earliest "upstream" events that begin within nascent FAs, i.e., enhanced recruitment of K2 to active β1, formation of GIV•K2•β1-integrin complexes, and integrin clustering and activation. Consequently, a myriad of "downstream" events within mature FAs are also derailed, e.g., their number and size; phosphoactivation of MLC, Akt, and FAK; and the activation of a previously defined feedforward loop (FAK↔pYGIV↔PI3K↔FAK \[[@bib33], [@bib38]\]). It is certainly possible that some of the post-receptor activation pathway/downstream signaling in PGxA mutant cells may reflect some of the impact of GIV\'s ability to bind the PTB domain of Tensin. However, the observed impact of GIV-PGxA on integrin activation observed earlier ([Figures 3](#fig3){ref-type="fig"}D and 3E) is unlikely to be due to GIV•Tensin interaction because tensin is recruited much later ([@bib59]) than the time points studied here and in mature focal adhesions (unlike GIV, which colocalizes with β1-integrin in nascent adhesions at the cell periphery \[[@bib38]\]) has been shown to be a part of downstream signaling pathway ([@bib5]) and is considered as largely dispensable for the early steps of integrin activation ([@bib58], [@bib8]).

The GIV•Kindlin-2•β1-Integrin Synergy May Have a Poor Prognosis in Breast Cancer {#sec2.6}
--------------------------------------------------------------------------------

Next, we asked if the observed allosteric synergy between GIV, K2, and β1-integrin we observe here and the impact of such synergy on sinister properties of tumor cells can be meaningful when assessing tumor behavior and/or prognosticating clinical outcome. First, we asked if the levels of expression of each of these three entities alone, or in combination, could impact one of the most important readouts of cancer aggressiveness, i.e., metastasis-free patient survival. To discern this, we chose to study a pooled cohort of patients ([@bib45], [@bib6], [@bib62]) with breast cancers who did not receive adjuvant chemotherapy, and hence, in them metastatic progression reflects natural disease progression and not resistance/selection under treatment. Samples were divided into "low" and "high" subgroups with regard to GIV (CCDC88A; Figure 6A), β1-integrin (ITGB1; Figure 6B) and K2 (FERMT2; Figure 6C) gene expression levels using the StepMiner algorithm ([@bib50]), implemented within the hierarchical exploration of gene-expression microarrays online (HEGEMON) software ([@bib14], [@bib61]). Kaplan-Meier analyses of the disease-free survival showed that high levels of expression of each alone was enough to carry a grave prognosis, i.e., a shorter metastasis-free survival ([Figures 6](#fig6){ref-type="fig"}A--6C). To determine if the levels of expression of these genes and a few other important genes implicated in some of the earliest steps of integrin activation interact synergistically as independent variables to impact survival of patients, we carried out a Cox proportional-hazards model ([@bib13]), which is a regression model that is commonly used as a statistical method for investigating the effect of several variables upon the time it takes for a specified event to happen, in this case, metastasis ([@bib13]). We found that, in this model, CCDC88A (GIV) significantly interacts with FERMT2 (K2), ITGB1 (β1-integrin), and TNS1, 4 (tensin) but not TLN1 (talin) ([Figure 6](#fig6){ref-type="fig"}D); FERMT2 (K2) only interacts with GIV ([Figure 6](#fig6){ref-type="fig"}E). ITGB1 interacted with GIV and tensin ([Figure 6](#fig6){ref-type="fig"}F); talin interacted primarily with ITGB1 ([Figure 6](#fig6){ref-type="fig"}G). Thus, of all the gene pairs tested, high GIV and K2 expression had a synergistic impact on shortening metastasis-free survival. These findings not only provide evidence for "interaction" between GIV and K2 at the levels of gene expression and expose its impact on survival outcome but also serves to further cement the role of the GIV•K2 interaction in tumor aggressiveness and progression to metastasis. Findings are also consistent with prior evidence that elevated levels of K2 carries a poor prognosis in a variety of cancers ([@bib66], [@bib70], [@bib20], [@bib10], [@bib40], [@bib42], [@bib51], [@bib53], [@bib57]).Figure 6Levels of Expression of GIV, Kindlin-2, and β1-integrin Prognosticate Progression to MetastasisPrimary breast cancers from 572 patients (three independent cohorts, pooled \[[@bib45], [@bib6], [@bib62]\]) who did not receive adjuvant therapy were segregated into groups of high versus low expression (see [Methods](#sec3){ref-type="sec"}) of target genes and analyzed for metastasis-free survival.(A--C) Kaplan-Meier curves for metastasis-free survival over time among patients whose primary tumors had high versus low levels of GIV (CCDC88A; A), β1-integrin (ITGB1; B) and K2 (FERMT2; C).(D--G) Statistical interaction (synergy between variables) is measured in the Cox proportional hazards regression model for CCDC88A (GIV; D), FERMT2 (K2; E), ITGB1 (β1-integrin; F), and TLN1 (talin; G) with other major genes involved in some of the earliest steps of integrin activation and the formation and maturation of the FAs. Coefficient of the interaction term in Cox regression models is plotted with 95% confidence interval that demonstrates the significance of the statistical interaction. ∗∗∗p = 0.001; ∗∗p = 0.01; ∗p = 0.05.

Conclusions {#sec2.7}
-----------

The major discovery we report herein is the mechanism and consequences of a direct interaction between GIV and K2. Using selective single point mutants of GIV that are incapable of binding K2, we chart the two major consequences of this GIV•K2 interaction. First, the GIV•K2 interaction impacts GIV biology because it appears to be a pre-requisite for the previously defined GIV-dependent signaling programs downstream of ligand-activated integrins, e.g., G protein (Gβγ→PI3K), PI3K→Akt, PI3K→FAK→pYGIV, and RhoA→MLC. Second, this interaction impacts integrin biology because it augments the affinity of K2 for the cytoplasmic tail of β1-integrins *in vitro*, the recruitment of K2 to β1-integrins in cells, and its subsequent clustering and activation within nascent and mature FAs.

As for the impact of the GIV•K2 interaction on GIV biology, findings showcased here, together with our understanding of how GIV modulates integrin/FAK signaling via G protein intermediates ([@bib34], [@bib33], [@bib38]), provide a more complete mechanistic insight into the roles of GIV in both early and late steps of integrin signaling ([Figure 7](#fig7){ref-type="fig"}A). Because integrin signaling aids cancer growth, metastasis, and drug resistance, the signaling interfaces assembled by GIV (GIV●K2 and GIV●Gαi) provide potentially impactful strategies for targeting the integrin pathway. Furthermore, GIV\'s FERM3/PTB-binding PGxF motif provides the second mechanism (GIV\'s SH2-like module was the first \[[@bib36]\]) by which GIV can couple Gα-proteins to non-GPCRs like integrins ([Figure 7](#fig7){ref-type="fig"}B), which are typically believed to initiate tyrosine-based signals. Because GIV binds the PTB domain of tensin, it is possible that the SLIM in GIV we define here, which binds K2-FERM3-PTB and tensin-PTB, may also recognize other PTB-module-containing adaptors. If so, it is possible that such versatility of the motif could enable coupling of GIV/G proteins, PI3K activation, and RhoA-dependent actin remodeling to diverse classes of non-GPCRs besides integrins that also use PTB proteins as adaptors, i.e., cytokine, LDL-receptor, leukocyte receptors, and RTKs ([@bib54]), leading to signal convergence.Figure 7Schematic Summarizing How GIV Impacts Early and Late Events in β1-integrin Signaling(A) Schematic illustrating the role of GIV during various steps of β1-integrin activation and signaling. Integrin activation is mediated by binding of its cytoplasmic tail to Talin (Step 1) and GIV•K2 complexes (Step 2). The latter is necessary for integrin clustering, activation, and maturation of focal adhesions (Step 3); activation of FAK; and tyrosine phosphorylation of GIV (Step 4). Previously described forward feedback loops (Step 5) orchestrated by G protein signaling further enhances integrin signaling.(B) Structural basis for how ligand-activated β1-integrins may bind and modulate trimeric G protein, Gαi via the assembly of K2•GIV complexes.(C) Binding of either GIV or β1-integrin on non-overlapping interfaces of K2 allosterically enhances the formation of GIV•K2•β1-integrin complexes.

As for the impact of the GIV•K2 interaction on integrin biology, its ability to allosterically augment the affinity of K2 for β1-integrins and enhance the activation of β1-integrins resembles how talin-dependent activation of β1-integrins is triggered by adjusting the affinity of talin for integrins. For example, binding of talin\'s FERM domain to charged acidic phospholipids, phosphatidylinositol 4,5-bisphosphate(PtdIns(4,5)P2), greatly increased its affinity for integrins, so that once talin is recruited to the plasma membrane, this phospholipid could augment the formation of talin-integrin complexes ([@bib47], [@bib67]). In fact, membrane recruitment of talin is sufficient to increase its affinity for integrins ([@bib28], [@bib31], [@bib22]).

In the case of K2, researchers generally agree that K2\'s adaptor functions may be critical for maximal integrin activation and clustering (reviewed in [@bib8]), but how the K2•β1-integrin interaction augments integrin activation remained unknown ([@bib4], [@bib25]). We have not only pinpointed GIV as one binding partner that adjusts the affinity of K2 for β1-integrins but also provided a molecular basis for how such adjustment of affinity is brought about through an intramolecular allostery within K2 ([Figure 7](#fig7){ref-type="fig"}C). Our findings that GIV and β1-integrin may augment each other\'s ability to bind K2-FERM3-PTB suggest that the interplay between integrin, K2, and GIV may serve as one of the long-sought missing early steps in integrin activation.

Limitations of the Study {#sec2.8}
------------------------

Despite gaining meaningful structural insights into the nature of the GIV•K2 interface, we were unable to generate a Kindlin construct that would selectively disrupt its ability to bind GIV without interrupting its ability to bind β1 integrins. Because our experiments showed that the GIV•K2 and K2•β1 interfaces allosterically modulate each other, generation of such specific K2 mutants may not be possible altogether. Whether GIV modulates other receptors that also use FERM3-PTB domain containing adaptors to relay downstream signals was not investigated in this study; it is possible that some of the phenotypes in cells expressing GIV mutants that cannot bind FERM3-PTB domains is due to convergent signaling downstream of other receptors that use such adaptors. Finally, it is possible that GIV also binds other PTB-domain containing adaptors. Whether this is possible is an ongoing investigation.
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